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Introduction
Renal cancer is estimated to have an incidence of 12.6/100 000 men in developed countries compared with only 3.4/100 000 women. (Torre et al., 2015) Therefore, androgens have been suspected to be involved in the initiation of renal cell carcinoma (RCC). Both male sex and obesity (BMI > 30) have implications for the incidence of renal cancer with a nearly two-fold risk, respectively (Sanfilippo et al., 2014) . Estrogen production from adipose tissue and the abundance of testosterone in men have led to investigations implicating the androgen receptor (AR) as a potential target (Feldman and Motzer, 2006) . The AR can be influenced by the amount of testosterone and dihydrotestoterone in circulation. Currently, studies have shown that higher AR expression found in RCC is associated with more aggressive cancer with advanced pathologic T stage and Fuhrman grade, possibly by induction of hypoxia-inducible factor-2α/vascular endothelial growth factor (VEGF) signaling He et al. 2014) . Finasteride or oral contraceptives may interact with the AR and thereby play a role in the natural history of RCC. We investigate the role of self-reported finasteride or oral contraceptive use in the Prostate, Lung, Colorectal, and Ovarian (PCLO) as it relates to the incidence of RCC in the PCLO screening study.
Methods

Study population
After internal review board approval and data transfer agreement (CDAS project # 120), we obtained de-identified data from participants enrolled in the PCLO Cancer Screening Trial. The PCLO is a National Cancer Institute-sponsored randomized trial investigating the effects of screening on cancer outcomes in patients aged 55-74 years from 1993 to 2001 and followed them for 13 years.
Outcomes and risk factors
The primary outcome of this study was the incidence of renal cancer defined by questionnaire and medical record confirmation in the context of the PCLO clinical trial. Predictor variables were obtained from the baseline questionnaire and follow-up questionnaires enquiring medication use, specifically the use of 5-α reductase inhibitors (5-ARI; dutasteride or finasteride) and oral contraceptive therapy (OCT). The WHO standard categorization of BMI was utilized. Hypertension was obtained by a questionnaire.
Statistical analysis
The PCLO database was queried for the primary outcome of renal cancer. Demographics were investigated, specifically focusing on medication predictor variables of 5-ARI and OCT medications controlling for previously identified risk factors of BMI and hypertension. Statistical analysis included testing for bivariate associations between renal cancer status and risk factors using the Student t-test for continuous variables, χ 2 , or Fisher's exact tests for dichotomous or categorical variables. The incidence of RCC was modeled using Cox proportional hazards models and all risk factors were considered within the same model adjusting for demographics and comorbidities.
Results
We obtained local internal review board approval and request to the PCLO for data with data-use agreement forms. We then investigated existing data on RCC incidence and the use of 5-ARI use in men and oral contraception in women.
5-α reductase inhibitor in men and renal cell carcinoma incidence
Eight percent (n = 6117/73 694) of men in the PCLO trial reported the use of finasteride by questionnaire. Only 52 (10.6%) of the 492 men diagnosed with renal cancer had self-reported exposure to finasteride and this was not significant in univariable analysis (52/6169; 0.84% vs. 440/66 454; 0.67%, P = 0.12) ( Table 1 ). In the multivariable main effects analysis, finasteride did not have an association with increased or decreased incidence of RCC in men (hazard ratio: 1.12; 95% confidence interval: 0.83-1.5; P = 0.47) adjusted for smoking, age, study arm, education, BMI, race/ethnicity, family history of renal cancer, and diabetes (Table 2) . Men who were exposed to finasteride also did not benefit from a delayed time in the onset of renal cancer (Fig. 1) . About 1.5% of men were excluded from the adjusted analysis because of missing covariates.
Oral contraceptive use in women and renal cell carcinoma incidence Approximately 54% of women (n = 40 997/75 989) in the PCLO trial reported the use of oral contraceptives by questionnaire. 136 (52.1%) of the 261 women diagnosed with renal cancer had self-reported exposure to OCT and this was not significant in univariable analysis (136/40 997; 0.33% vs. 125/34 992; 0.36%, P = 0.36). In the multivariable main effects analysis, contraceptive use did not have an association with increased or decreased incidence of RCC in women (hazard ratio: 1.03; 95% confidence interval: 0.97-1.1; P = 0.30) adjusted for smoking, age, study arm, education, BMI, race/ethnicity, family history of renal cancer, and diabetes (Table 3) . Women who used oral contraceptives did not benefit from a delayed time in the onset of renal cancer (Fig. 2) . About 0.01% of women were excluded from the adjusted analysis because of missing covariates.
Discussion
The increased incidence of RCC in men compared with women suggests a possible sex-linked risk factor. We queried the PCLO study to determine the effects of finasteride use on the incidence of RCC. Our analysis of the more than 79 000 men in the PCLO study showed that a self-reported use of finasteride is not associated with a reduced incidence of RCC. In addition, oral contraceptive use was not associated with the incidence of RCC in women either. However, the concept of hormonal manipulation has been robust in animal models. A recent study by Tian et al. (2015) described the use of finasteride to reduce microvessel density, VEGF protein expression in glomeruli, and VEGF mRNA expression in the renal cortex tissue in diabetic rats (all P <0.05). Urologists use finasteride to reduce microvessel density in men with hematuria from enlarged prostates. Moreover, finasteride has shown a reduction in prostate cancer formation in the prostate cancer prevention trial. Therefore, we sought to investigate whether this could prevent renal masses by this mechanism, although we have shown this not to be the case in our data set.
The effects of estrogen on renal tumors have stimulated interest in the role of female hormonal and reproductive factors in the development of renal cancer. Exogenous estrogens have been shown in animals to promote and induce renal cancer formation (Cavalieri et al., 2001) , and sex hormone receptor expression in both normal and malignant renal tissue suggests that endocrine regulation could directly influence renal cancer development. Moreover, estrogens also influence the catechol-estrogen pathway and also produce related reactive-oxygen species. These pathways have been well described in breast cancer and have also have been linked to the AKT pathway, which plays a prominent role in renal cancer (Fussell et al., 2011) ; (Habib and Liang, 2014) . Our analysis did not suggest an association between oral contraceptives and the incidence of RCC, but other studies have (insert reference). Anatomical changes to the renal during pregnancy might make nephrons more vulnerable to inflammation and oxidative stress. Finally, hormonal disturbance has been associated with obesity and smoking (Cramer et al., 1995) , two major risk factors observed most consistently across renal cancer studies.
The link between AR and the incidence of RCC has been less clear in patients. Several studies showed loss of AR in RCC in conjunction with increasing clinical stage and pathological grade (Langner et al., 2004; Zhu et al., 2014) , but others found that higher AR expression was correlated with worse outcomes. Limited functional studies with renal cell lines suggested the tumor-promoting activity of AR (Ha et al., 2015) . There may be significant clinical implications and development of treatment strategies after a clear understanding of this relationship. Finasteride and renal cancer incidence. Covariate-adjusted survival curve noting the incidence of renal cancer in men who did and did not indicate that they had taken finasteride by a standardized Prostate, Lung, Colorectal, and Ovarian questionnaire. CI, confidence interval; HR, hazard ratio. Oral contraception and renal cancer incidence. Covariate-adjusted survival curve noting the incidence of renal cancer in women who did and did not indicate that they had taken oral contraception by a standardized Prostate, Lung, Colorectal, and Ovarian questionnaire. CI, confidence interval; HR, hazard ratio; OCT, oral contraceptive therapy. It is evident that there is a relationship between RCC and the hormonal pathway. Further studies will be needed to elucidate the actual relationship and mechanisms involved to be able to use possible preventive or therapeutic targets. However, clinical trials for this concept would be difficult because of the large sample size needed and the small population of men developing renal cancer.
Limitations of the study include the exclusion of young adults and children as the PCLO trial entry age was limited to 55-74 years. Children and young adults are not necessarily at risk for these cancers; however, renal cell cancer has been known to affect both sexes in the third and fourth decades of life and may alter our findings if included. In addition, the use of finasteride or OCT is based on questionnaire data that could lead to recall bias and the inability to carry out a dose-related response analysis because of small numbers.
Conclusion
Despite the recent excitement surrounding the AR as a target for the prevention of RCC, our analysis of the PCLO study showed that a self-reported use of finasteride or oral contraceptives is not associated with a reduced incidence of renal cancer. However, further studies will be needed to elucidate the actual relationship and mechanisms involved to be able to use possible preventive or therapeutic targets in the future.
